ライフサイエンスコーパス: urokinase receptor

1 asminogen activator inhibitor type-1 and the urokinase receptor.

2 A-dependent ERK signaling via an alternative urokinase receptor.

3 s were confirmed on cells expressing variant urokinase receptor.

4 occur through interactions with endothelial urokinase receptors.

5 Since the binding of urokinase to urokinase receptors activates signaling responses and ma

6 Because urokinase receptor.alpha5beta1 complexes bind in the fib

7 ed growth factor, matrix metalloproteinases, urokinase receptor and varied small-molecule tyrosine ki

8 as decreased expression of c-met, urokinase, urokinase receptor, and TGF-beta1.

9 n of metastasis, these findings suggest that urokinase receptor antagonists may be useful therapeutic

10 ands and a basis for the design of urokinase-urokinase receptor antagonists.

11 portion of human IgG as high-affinity murine urokinase receptor antagonists.

12 Urokinase receptors bind urokinase and a set of beta1 in

13 We found that uPAR ligation with the urokinase receptor binding domain (amino-terminal fragme

14 Thus urokinase receptor binding to alpha5beta1 is required fo

15 he crystal structure at 1.9 angstroms of the urokinase receptor complexed with the urokinase amino-te

16 Although Mrc2 associates with the urokinase receptor, differences in renal urokinase activ

17 ocyte antigen, PLAUR (plasminogen activator, urokinase receptor) domain-containing (LYPD)-6B on alpha

18 xperiments using nuclear extract from a high urokinase receptor-expressing cell line (RKO) indicated

19 urokinase receptor promoter activity in low urokinase receptor-expressing GEO cells was increased by

20 ine if a constitutively active Src regulates urokinase receptor expression and 2) to identify require

21 elements and trans-acting factors activating urokinase receptor expression through a footprinted (-14

22 yristate 13-acetate treatment, which induces urokinase receptor expression, increased complex formati

23 eceptor promoter (-152/-135) in constitutive urokinase receptor expression, we determined its role fo

24 The three domains of urokinase receptor form a concave shape with a central c

25 vely active Src protein manifested increased urokinase receptor gene expression and Src activity.

26 These data suggest that urokinase receptor gene expression is regulated by Src p

27 grins, but it remains unclear to what degree urokinase receptor/integrin binding is important to beta

28 The urokinase receptor is composed of three homologous domai

29 state 13-acetate-inducible expression of the urokinase receptor is mediated partly through trans-acti

30 Up-regulation of urokinase receptors is common during tumor progression a

31 PLAP and the carboxy-terminal portion of the urokinase receptor (MP/uPAR) into which various amino ac

32 The urokinase receptor overexpressed in invasive cancers pro

33 the GEO cells which have approximately 10(4) urokinase receptors per cell.

34 ecently implicated an upstream region of the urokinase receptor promoter (-152/-135) in constitutive

35 Conversely, urokinase receptor promoter activity in low urokinase re

36 r of activator protein-2 function diminished urokinase receptor promoter activity, protein, and lamin

37 tor protein 2alpha-related factor diminished urokinase receptor promoter activity.

38 a-related factor and Sp1/Sp3 binding reduced urokinase receptor promoter stimulation by this agent.

39 Finally, endogenous urokinase receptor protein amounts in 10 colon cancers a

40 vasiveness and because both Src activity and urokinase receptor protein are elevated in invasive colo

41 ants with a Src-inhibitor (PD173955) reduced urokinase receptor protein levels and laminin degradatio

42 Knockdown of urokinase receptors resulted in markedly reduced fibrone

43 Overexpression of soluble urokinase receptor (suPAR) causes pathology in animal mo

44 Recently, serum soluble urokinase receptor (suPAR) has been proposed as a cause

45 Here we report that serum soluble urokinase receptor (suPAR) is elevated in two-thirds of

46 Serum soluble urokinase receptor (suPAR) levels strongly predict incid

47 provides insight into the flexibility of the urokinase receptor that enables its interaction with a w

48 inogen (Pg(-)(/-)), urokinase (u-PA(-)(/-)), urokinase receptor (u-PAR(-)(/-)), or tissue plasminogen

49 The urokinase receptor (u-PAR) which is largely regulated at

50 Expression of the urokinase receptor uPAR is essential to the development

51 Hypoxia induces expression of the urokinase receptor (uPAR) and activates uPAR-dependent c

52 uantitative increases in urokinase PA (uPA), urokinase receptor (uPAR) and plasminogen activator inhi

53 s significantly increased levels of cellular urokinase receptor (uPAR) and release increased amounts

54 The nonintegrin urokinase receptor (uPAR) associates with and stabilizes

55 The urokinase receptor (uPAR) attenuates myofibroblast recru

56 Although the urokinase receptor (uPAR) binds to vitronectin (VN) and

57 The urokinase receptor (uPAR) binds urokinase-type plasminog

58 The urokinase receptor (uPAR) coordinates plasmin-mediated c

59 e that in EGFRvIII-expressing GBM cells, the urokinase receptor (uPAR) functions as a major activator

60 etermine the role of urokinase (uPA) and the urokinase receptor (uPAR) in retinal angiogenesis, and w

61 The urokinase receptor (uPAR) is a cell-signaling receptor k

62 The urokinase receptor (uPAR) is a glycosylphosphatidylinosi

63 Given that the urokinase receptor (uPAR) is known to play a role in cel

64 The urokinase receptor (uPAR) is linked to cellular migratio

65 Neither the urokinase receptor (uPAR) nor the low-density lipoprotei

66 The urokinase receptor (uPAR) plays an important role in reg

67 The urokinase receptor (uPAR) promotes metastasis of human m

68 Here we show that induction of urokinase receptor (uPAR) signaling in podocytes leads t

69 These cells overexpress urokinase receptor (uPAR) which, by activating alpha5bet

70 here we report the sequestration behavior of urokinase receptor (uPAR), a glycosylphosphatidylinosito

71 CDC91L1 also resulted in upregulation of the urokinase receptor (uPAR), a GPI-anchored protein, and i

72 , through unknown receptors, overexpress the urokinase receptor (uPAR), a key mediator of the plasmin

73 A second integrin ligand, the urokinase receptor (uPAR), associates with alpha3beta1 v

74 One such protein, the glycolipid-anchored urokinase receptor (uPAR), associates with and modifies

75 The urokinase receptor (uPAR), expressed on the surface of m

76 urokinase-type plasminogen activator (uPA), urokinase receptor (uPAR), tissue-type plasminogen activ

77 ted on the surface of many cell types, where urokinase receptor (uPAR)-bound urokinase (uPA) activate

78 nse to EGF only when these cells express the urokinase receptor (uPAR).

79 inogen activator inhibitor-1 (PAI-1) and the urokinase receptor (uPAR).

80 ator inhibitor complexes (uPA:PAI-1) and the urokinase receptor (uPAR).

81 ly on endothelial cells to domain 2/3 of the urokinase receptor (uPAR).

82 lls, which express both LRP/alpha2MR and the urokinase receptor (uPAR).

83 eukocyte integrin Mac-1 (CD11b/CD18) and the urokinase receptor (uPAR, CD87) mediate complementary fu

84 ase-type plasminogen activator (uPA) and the urokinase receptor (uPAR, CD87).

85 R4 physically and functionally interact with urokinase receptors (uPAR) on neutrophil plasma membrane

86 beta2 integrins for substrate attachment and urokinase receptors (uPAR) to focus pericellular proteol

87 Urokinase receptors (uPAR; CD87) from complexes with com

88 Leukocytes use urokinase receptors (uPAR; CD87) in adhesion, migration,

89 Leukocytes utilize urokinase receptors (uPAR; CD87) in adhesion, migration,

90 hly colocalized on the cell surface with the urokinase receptor, uPAR.

91 The urokinase receptor urokinase-type plasminogen activator

92 Binding to the urokinase receptor was completely abolished while PAI-1

93 utagenesis, single amino acid mutants of the urokinase receptor were identified that fail to associat

94 tions on beta1 integrin function, endogenous urokinase receptors were first stably silenced in tumor

95 ffract in the co-crystal, and a site for the urokinase receptor, which overlaps with the PAI-1-bindin